Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

Phase 3 Completed 227 enrolled University Hospital, Lille Erasme University Hospital · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.

Timeline

Start: 2001-05
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Daclizumab	Monoclonal antibody	1 mg/kg	—
Comparator	Thymoglobulin	Protein / enzyme biologic	1.25 mg/kg	—

Indications

No indication recorded.